The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.
Guo-ping Sun
No relevant relationships to disclose
Yan Sun
No relevant relationships to disclose
Rui-hua Xu
No relevant relationships to disclose
Jian-Ming Xu
No relevant relationships to disclose
Jin Li
No relevant relationships to disclose
Jin-Wan Wang
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose
Ji Feng Feng
No relevant relationships to disclose
Yi Ba
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose
Yu-Xian Bai
No relevant relationships to disclose
Yihong Sun
No relevant relationships to disclose
Hongming Pan
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Shiying Yu
No relevant relationships to disclose
Haijun Zhong
No relevant relationships to disclose
Li Bai
No relevant relationships to disclose
Rongcheng Luo
No relevant relationships to disclose
Mikiro Kobayashi
No relevant relationships to disclose
Atsushi Ohtsu
No relevant relationships to disclose